Evidence map›Paper›PMID 40782270›Full record

ArticleJournal of computer-aided molecular design2025

Ai-driven de novo design of customizable membrane permeable cyclic peptides.

Yu Yunxiang, Zhang Zhou, Guo Hai, Ren Xinlu, Zhang Yuting, Meng Jianna, Zhou Yi, Han Jian, Tian Jinhui, Yan Wenjin and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yu Yunxiang *School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu, China.
Zhang Zhou *School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu, China.
Guo HaiThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, China.
Ren XinluSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu, China.
Zhang YutingThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, China.
Meng JiannaSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu, China.
Zhou YiSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu, China.
Han JianSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu, China.
Tian JinhuiSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu, China.
Yan WenjinSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu, China. yanwj@lzu.edu.cn.
Huang JinqiInstitute of Blood Transfusion and Hematology, Guangzhou First People's Hospital, Guangzhou, 510080, Guangdong, China.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515220122National Natural Science Foundation of China 82470231
6 · The paper itself

Abstract

Cyclic peptides, prized for their remarkable bioactivity and stability, hold great promise across various fields. Yet, designing membrane-penetrating bioactive cyclic peptides via traditional methods is complex and resource-intensive. To address this, we introduce CCPep, an AI-driven de novo design framework that combines reinforcement and contrastive learning for efficient, customizable membrane-penetrating cyclic peptide design. It assesses peptide membrane penetration with scoring models and optimizes transmembrane ability through reinforcement learning. Customization of peptides with specific properties is achieved via custom functions, while contrastive learning incorporates molecular dynamics simulation time series to capture dynamic penetration features, enhancing model performance. Result shows that CCPep generated cyclic peptide sequences have a promising membrane penetration rate, with customizable chain length, natural amino acid ratio, and target segments. This framework offers an efficient tool for cyclic peptide drug design and paves the way for AI-driven multi-objective molecule design.

Indexed as

Artificial IntelligenceCell-Penetrating PeptidesDrug DesignPeptides, CyclicAmino Acid SequenceCell Membrane PermeabilityMolecular Dynamics SimulationCell-Penetrating PeptidesPeptides, CyclicCyclic peptideMolecular DynamicPermeabilityReinforcement Learning

Identifiers

PMID40782270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.